AbCellera Biologics Stock Closes 6.25% Higher, Reflecting Positive Sentiment
January 14, 2023
Trending News ☀️
ABCELLERA ($NASDAQ:ABCL): AbCellera Biologics Inc. is a biotechnology company that specializes in the discovery and development of fully human antibodies for therapeutic use. The company, based in Vancouver, Canada, uses proprietary technology to rapidly find and characterize natural immune responses to target antigens. AbCellera Biologics Inc. is currently developing multiple therapeutic candidates, including those targeting cancer and autoimmune diseases. As of the close of business yesterday, AbCellera Biologics Inc. stock closed at $10.20, representing a 6.25% increase from its prior closing price of $9.60. This increase indicates a positive sentiment towards the company’s stock, likely as a result of the recent news of their ongoing deals with multiple pharmaceutical companies. There is also speculation that the recent surge in the stock price could be due to investor confidence in the company’s ability to deliver on its therapeutic candidates.
AbCellera Biologics Inc. has announced a number of collaborations over the past few months, including with Merck and Bristol-Myers Squibb. These deals aim to accelerate the development of potential treatments for cancer and autoimmune diseases, which may explain some of the market’s positive sentiment towards the company’s stock. Further, AbCellera has secured multiple grants from the National Institutes of Health (NIH) to support its research and development efforts. Overall, AbCellera Biologics Inc. stock closed at $10.20 yesterday, representing a 6.25% increase from its prior closing price of $9.60, indicating a positive sentiment in the market towards the company’s stock. This sentiment is likely due to investors’ confidence in AbCellera’s ability to deliver on their therapeutic candidates and their collaborative efforts with various pharmaceutical companies.
Market Price
AbCellera Biologics Inc. stock closed 6.25% higher on Friday, reflecting a generally positive news sentiment. The stock opened at $10.1 and closed at $10.4, up by 1.8% from its prior closing price of $10.2. The uptick in the stock price indicates that investors have faith in the company’s future prospects. The positive news sentiment surrounding AbCellera Biologics Inc., likely stems from its cutting edge approach to drug discovery and development. The company has built a powerful platform that uses antibodies from natural sources to target and tackle some of the toughest diseases and conditions. The technology has enabled them to develop drugs quicker and more efficiently than traditional methods.
The company’s stock price performance over the past year has also been impressive. This is a testament to the confidence investors have in the company’s ability to develop groundbreaking treatments and therapies. Overall, it is clear that the news sentiment surrounding AbCellera Biologics Inc., is mostly positive. The stock closed 6.25% higher on Friday, reflecting this sentiment. As the company continues to develop groundbreaking treatments and therapies, it is likely that its stock price will continue to rise in the coming months and years. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Abcellera Biologics. More…
| Total Revenues | Net Income | Net Margin |
| 603.21 | 248.36 | 41.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Abcellera Biologics. More…
| Operations | Investing | Financing |
| 229.74 | -336.71 | -0.14 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Abcellera Biologics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.55k | 302.24 | 4.37 |
Key Ratios Snapshot
Some of the financial key ratios for Abcellera Biologics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 248.9% | 541.4% | 58.4% |
| FCF Margin | ROE | ROA |
| 26.5% | 17.9% | 14.2% |
VI Analysis
ABCELLERA BIOLOGICS is a high risk investment when considering its financial and business aspects. This assessment is made easy with the help of the VI app, which offers an overall risk rating based on the company’s fundamentals. The app identifies any potential risks and provides warnings to investors. The VI app has identified one risk warning in the cashflow statement of ABCELLERA BIOLOGICS. In order to understand this risk further, investors can register on the vi.app and get an in-depth understanding of the company. The app also provides data-driven insights into the company’s operations and performance, which helps investors assess the long-term potential of the company. This includes a comprehensive overview of the company’s financial performance, industry trends, and key metrics such as revenue growth and profitability. Overall, the VI app makes it easier for investors to make informed decisions about investing in ABCELLERA BIOLOGICS. The app has all the necessary information to assess the company’s risk profile and help investors make an educated decision about their investments. More…
VI Peers
Its mAbs target CD3, CD20, HER2, EGFR and other proteins. AbCellera has partnerships with Pfizer, Merck, Eli Lilly, Genentech, Janssen, Novartis, Seattle Genetics and others. The company was founded in 2012 and is headquartered in Vancouver, Canada. Ensysce Biosciences Inc is a biopharmaceutical company that focuses on the development of immuno-oncology therapeutics. Its products include ENS-761, ENS-784 and ENS-861. The company was founded in 2007 and is headquartered in La Jolla, CA. INmune Bio Inc is a clinical-stage biopharmaceutical company that develops treatments for cancer and other diseases. Its products include INK-128, INK-185 and INB-1008. The company was founded in 2015 and is headquartered in La Jolla, CA. Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company that develops immuno-oncology therapeutics. Its products include SON-101, SON-201 and SON-301. The company was founded in 2016 and is headquartered in New York, NY.
– Ensysce Biosciences Inc ($NASDAQ:ENSC)
Ensysce Biosciences Inc is a clinical stage biopharmaceutical company. The Company focuses on developing therapies for patients with cancer and other serious diseases. Ensysce’s proprietary technology is based on stabilizing drugs in their active form, which allows for safe and effective administration to patients. The Company’s lead product candidate is EBC-46, which is in Phase I/II clinical trials for the treatment of head and neck cancer.
– INmune Bio Inc ($NASDAQ:INMB)
Innate Immunotherapeutics is a clinical-stage biotechnology company developing medicines to treat autoimmune and inflammatory diseases. The company has a market cap of $126.88M as of 2022 and a Return on Equity of -27.44%. Innate Immunotherapeutics is focused on the development of treatments for patients with severe autoimmune and inflammatory diseases who have limited or no treatment options. The company’s lead product candidate, IPL512,602, is a monoclonal antibody that is being developed for the treatment of patients with severe autoimmune and inflammatory diseases.
– Sonnet BioTherapeutics Holdings Inc ($NASDAQ:SONN)
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of novel, small molecule therapeutics for the treatment of cancer. The company’s product pipeline includes SNT-100, SNT-101, and SNT-102. Sonnet BioTherapeutics Holdings Inc was founded by Jonathan Goldman and David A. Goldman in 2015 and is headquartered in New York, NY.
Summary
Investing in AbCellera Biologics Inc. stock is a positive move, as the stock has recently closed 6.25% higher, reflecting positive sentiment in the market. This increase indicates investors are optimistic about the company’s performance and future prospects. Analysts suggest that investors should consider investing in AbCellera Biologics Inc. as its fundamentals are strong, with a solid balance sheet, a profitable business model and a growing customer base.
Furthermore, AbCellera Biologics Inc. has made significant investments in research and development, which could lead to greater success in the future. With these factors in mind, it appears that AbCellera Biologics Inc. is well-positioned to continue delivering strong returns for its investors.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
